Vyvanse (lisdexamfetamine) for adults

Vyvanse (lisdexamfetamine dimesylate) is a long-acting stimulant with two FDA-approved uses in adults: ADHD and moderate to severe binge eating disorder. Since 2023 it has also been sold as a generic. This page summarizes the current FDA label (updated April 30, 2026) and adds the supply, guideline and New York and New Jersey context adults usually ask about. It is general information, not advice to start, stop or change any medication.

What it is: a prodrug

Lisdexamfetamine is a "prodrug of dextroamphetamine," in the label's words. The capsule or chewable tablet contains lisdexamfetamine, which does little on its own. After it is swallowed, it is converted to dextroamphetamine (the active stimulant) and the amino acid l-lysine, mainly in the blood through the activity of red blood cells. The label adds that lisdexamfetamine itself "is not metabolized by cytochrome P450 enzymes."

That conversion step is what makes Vyvanse long-acting. It belongs to the amphetamine family of CNS stimulants, and federal law lists lisdexamfetamine in Schedule II. For how prodrugs compare with bead capsules and other designs, see extended-release ADHD medications explained.

Is it approved for adults?

Yes, for two conditions. The label says Vyvanse is indicated for:

• "Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older"
• "Moderate to severe binge eating disorder (BED) in adults"

The label is explicit that Vyvanse "is not indicated or recommended for weight loss" and that its safety and effectiveness for obesity have not been established. It is also not recommended for children under 6.

What the adult studies showed

The label describes three adult ADHD studies, all in people aged 18 to 55:

• A four-week placebo-controlled trial (420 adults): every Vyvanse group improved more than placebo on the ADHD Rating Scale.
• A simulated workplace study (142 adults): attention, measured with a timed math test, was better on Vyvanse than placebo at every time point tested, from 2 hours through 14 hours after the dose.
• A maintenance study (123 adults already doing well on Vyvanse): during a six-week double-blind phase, 9% of those who stayed on Vyvanse met the definition of treatment failure, compared with 75% of those switched to placebo.

For older adults, the label says studies did not include enough people 65 and over to tell whether they respond differently.

Where it sits in guidelines

The UK's NICE guideline (NG87) recommends offering lisdexamfetamine or methylphenidate as first-line medication for adults with ADHD. A 2018 network meta-analysis in Lancet Psychiatry found amphetamines had the largest effect on clinician-rated symptoms in adults and supported amphetamines as a first choice for adults in short-term treatment. For a side-by-side view, see Adderall vs Vyvanse and Vyvanse vs Concerta.

Forms

• Capsules: swallowed whole, or opened and the entire contents mixed with yogurt, water or orange juice and taken right away.
• Chewable tablets: must be chewed thoroughly before swallowing.

The label says to take it in the morning, with or without food, and to avoid afternoon doses because of insomnia. It also lowers the maximum for severe kidney impairment and end-stage renal disease.

The boxed warning

Vyvanse carries the CNS stimulant boxed warning on abuse, misuse and addiction, which the FDA required across the class on May 11, 2023. Being a prodrug does not remove that warning: the label still describes a high potential for abuse and misuse that can lead to a substance use disorder, including addiction, and says prescribers should assess and keep reassessing each person's risk. See misuse and addiction risk.

Common side effects

For ADHD, the label lists the most common adverse reactions in children and adults (at least 5% and at least twice the placebo rate) as loss of appetite, anxiety, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain and vomiting. In adults treated for binge eating disorder, the most common were dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery and anxiety.

The label's serious warnings match the rest of the class: risks for people with serious heart disease, raised blood pressure and heart rate, psychiatric effects including mania and psychosis, circulation problems in fingers and toes, serotonin syndrome, and tics. See heart health and blood pressure.

Who should not take it

• People with known hypersensitivity to amphetamine products or other ingredients. The label notes anaphylaxis, Stevens-Johnson syndrome, angioedema and hives in postmarketing reports.
• People taking an MAOI or within 14 days of stopping one, including linezolid or intravenous methylene blue.

Interactions to mention

• MAOIs (contraindicated).
• Serotonergic drugs and CYP2D6 inhibitors (risk of serotonin syndrome).
• Agents that change urine pH: alkalinizing agents raise amphetamine levels and acidifying agents lower them.
• Tricyclic antidepressants.
• DaTscan imaging (ioflupane), which the label says amphetamines can interfere with.

See ADHD medication drug interactions.

Pregnancy and breastfeeding

The label says available data on Vyvanse in pregnancy "are not sufficient to inform a drug-associated risk for major birth defects and miscarriage," and that premature delivery and low birth weight have been seen in infants of mothers dependent on amphetamines. A pregnancy registry collects outcomes. The label advises that breastfeeding is not recommended during treatment. NIH LactMed notes that some experts consider prescribed amphetamine doses usable while nursing with infant monitoring, though manufacturers advise against it. See ADHD in pregnancy and postpartum.

Generics and the shortage

The FDA announced in August 2023 that it had approved several first generics of Vyvanse capsules and chewable tablets. Your pharmacy and plan can tell you what you would pay for brand or generic. Supply has been tight: as of October 19, 2026, the FDA shortage database lists lisdexamfetamine capsules and chewable tablets with a status of "Current," a shortage first posted in July 2023. For practical steps, see the shortage in New York and the shortage in New Jersey.

New York and New Jersey rules

As a Schedule II drug, lisdexamfetamine cannot be refilled under federal rules; a prescriber may issue multiple dated prescriptions covering up to 90 days.

• New York requires an I-STOP registry check and has its own supply and timing rules: New York's stimulant rules.
• New Jersey's P.L.2026, c.40 (effective July 8, 2026) requires adults located in New Jersey who start by telehealth to have an in-person visit within 30 days, a contact every three months and an in-person visit at least yearly; state rules also require an NJPMP check and a treatment plan before a controlled substance is started: New Jersey's rules.
• Federally, the DEA telemedicine flexibilities run through December 31, 2026, as of October 2026.

Dr. Shershow is a psychiatrist licensed in New York and New Jersey who provides medication management for adults when medication is appropriate. The office can explain how visits are arranged for patients located in New Jersey.

Questions to ask your prescriber

• Is a prodrug a better fit for my day than a bead capsule or a short-acting tablet?
• If my pharmacy is out of stock, can we use the chewable tablet or another strength?
• How will we track appetite, weight, sleep and blood pressure?
• I also binge eat. Does that change the plan?

More questions are in questions to ask before starting ADHD medication.